### **Company Overview** Navin Fluorine International Limited (NFIL), established in 1967, is one of India’s largest integrated specialty fluorochemical manufacturers and a flagship company of the Padmanabh Mafatlal Group. With over **50 years of expertise in fluorine chemistry**, the company has pioneered the manufacturing of refrigerants in India and remains the **only Indian producer of hydrofluoroolefins (HFOs)**, a next-generation, low-global-warming refrigerant. NFIL operates across three core business segments: 1. **High Performance Products (HPP)** – Refrigerants, inorganic fluorides 2. **Specialty Chemicals** – Agrochemical and pharmaceutical intermediates 3. **Contract Development and Manufacturing Organization (CDMO / Navin Molecular)** – Custom synthesis for global life sciences innovators The company serves over **900 customers globally** across North America, Europe, Asia Pacific, and the Middle East, with **~65% of revenues derived from international markets**. It operates manufacturing facilities in **Surat, Dahej (Gujarat), and Dewas (Madhya Pradesh)**, with a strategic international footprint through its UK subsidiary, **Manchester Organics Limited (MOL)**. --- ### **Strategic Positioning & Core Competencies** #### **1. Leadership in Fluorine Chemistry** - One of **India’s largest producers** of anhydrous and diluted hydrofluoric acid (AHF/HF), ammonium bifluoride, potassium fluoride, and sodium fluoride. - **Global leader** in boron trifluoride (BF₃) production and owns **India’s only high-pressure fluorination plant with cGMP compliance**, giving it a rare technical edge in niche fluorinated molecule manufacturing. - Backward integration into critical raw materials via a **25% stake in India’s sole fluorspar beneficiation joint venture**, reducing China dependency and enhancing supply chain resilience. #### **2. 3P Growth Strategy (Product, Platform, Partnerships)** This foundational strategy drives sustainable R&D-led growth: - **Product**: Expanding from commodity fluorides into high-value KSMs (Key Starting Materials), HFOs, R32 refrigerants, and electronic-grade chemicals. - **Platform**: Proprietary fluorination, continuous flow, biocatalysis, high-pressure, and cryogenic technologies that serve as building blocks for diverse life science and industrial applications. - **Partnerships**: Deep collaborations with global innovators including **Chemours, Honeywell, Fermion (European CDMO), and top-20 pharma and agrochemical firms**. #### **3. Integrated R&D Ecosystem** NFIL has established a **robust global R&D network** comprising three centers: - **Navin Research & Innovation Centre (NRIC), Surat (DSIR-approved):** Over 150 chemists and 50+ engineers focused on fluorinated specialty chemicals, new product platforms, and process innovation. Supports HPP and Specialty businesses. - **Navin Molecular R&D Centres (Dewas, India and Manchester, UK):** Over 100 scientists in R&D, analytical, and technology transfer roles. Specializes in preclinical to commercial scale contract development for global pharma and biotech clients. - Investment in R&D stood at **₹54.69 crore in FY25**, underscoring long-term commitment to innovation. R&D initiatives include: - **Biocatalysis** for chiral molecule synthesis (green chemistry). - **Flow chemistry** implementation for hazardous reactions. - **Ozonation and enzymatic processes** scaled to commercial levels. - Technology absorption from global partners via joint ventures and licensing. --- ### **Recent Developments & Strategic Initiatives (2024–2025)** #### **1. Capacity Expansions & Capital Investments** NFIL has executed a **robust CAPEX roadmap (₹700–1,000 crore annually)** to support long-term capacity and capability building: | **Project** | **Capex (₹ crores)** | **Status / Timeline** | |------------|----------------------|------------------------| | **Fluoro Specialty Plant (Dahej)** | ₹540 | Commissioned Dec 2024; ramping up; expected to contribute significantly in current fiscal | | **AHF Plant (Dahej)** | ₹450 | Scheduled for commissioning Q2 FY26 | | **cGMP4 Expansion** | ₹288 (Phase I: ₹160) | Phase I on track for Q3 FY26 commissioning; Phase II modular, likely tied to major EU CDMO partner | | **HFC-32 Refrigerant Capacity** | ₹84 | Expansion completed; plant now operating above capacity | | **Agro-Intermediate Plant (Surat)** | ₹30 | Operational from Q4 FY24–25 | | **Chemours Opteon™ Plant (Surat)** | $14 million (~₹114 cr) | Expected operational Q1 FY27 (Apr–Jun 2026) | - Strategic shift toward **modular and scalable** capex, enabling responsive customer alignment and de-risked investment. - Over **₹1,000 crores in aggregate capex** committed in past 18 months, signaling strong confidence in growth visibility. #### **2. Strategic Partnerships & Market Diversification** - **Chemours Collaboration**: Exclusive partnership to **manufacture Opteon™ two-phase immersion cooling fluid** for AI-driven data centers. Offers: - Ultra-low GWP (10), 90% reduction in cooling energy, space savings (~60%), and water-free operation. - Represents entry into **high-growth Advanced Materials and Electronic Chemicals sector**. - Project underpins NFIL’s transition toward sustainable, high-margin thermal solutions. - **BUSS ChemTech AG (Switzerland)**: Partnership to **commercialize electronic-grade HF** for semiconductor and solar applications. Initial supplies expected Q2 FY26. - **Fermion (EU CDMO)**: Multi-year MSA with expanded scope from 1 to 3 molecules; firm orders and validation underway. - **Honeywell**: Ongoing collaboration on HFOs and fluorinated building blocks. #### **3. CDMO Business – Navin Molecular** - Rebranded in 2024 to reflect broader chemistry capabilities beyond fluorination. - Focus: **Late-stage (Phase II/III) and commercial molecules** to stabilize revenue; target **50–55% revenue from commercial applications by FY26**. - Revenue grew **31% YoY to ₹343 crore in FY24–25**, driven by late-stage campaigns and new MSAs. - **$100 million revenue target** for CDMO segment seen as inflection point; a major U.S. commercial molecule could scale the division akin to its Fermion business. - cGMP4 facility will **more than double CDMO commercial capacity**, with strong order book and FDA/EMA-aligned compliance. --- ### **Financial & Operational Highlights** - **Revenue (FY24–25):** ₹800 crore (down 6% YoY due to agrochemical destocking and pharma demand softness, but underlying segments show recovery). - **EBITDA Margin:** Sustained ~19–27% range despite input cost volatility; targeted improvement in FY25–26 via capacity utilisation and cost leadership. - **Order Book:** Strong visibility in **FY26**, especially in CDMO and HPP, backed by firm MSAs and take-or-pay contracts. - **Capacity Utilisation:** Optimal at Dahej and Surat plants. PAR (Peak Annual Revenue) utilisation at Dahej MPP ~70%, with full ramp-up expected by FY27. - **Revenue Mix (FY24–25):** - **CDMO (Navin Molecular):** 34% - **HPP (Refrigerants, Inorganics):** 41% - **Specialty Chemicals (Agro/Pharma Intermediates):** 25%